The world is waiting ----SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and pre-clinical studies at the European Society for Medical Oncology (ESMO) 2014 Congress, to be held September 26-30 in Madrid, Spain. OncoSec is proud to be presenting an abstract titled, “Immune correlates of intratumoral IL-12 electroporation”, as part of a poster presentation taking place 12:45 PM - 1:45 PM CEST on Sunday, September 28th. “The data we are presenting support the ability of intratumoral electroporation of IL-12 to generate not just a local anti-tumor response, but evidence of response in distant lesions” “The data we are presenting support the ability of intratumoral electroporation of IL-12 to generate not just a local anti-tumor response, but evidence of response in distant lesions,” said Robert H. Pierce, M.D., Chief Medical Officer at OncoSec. “Additionally, pharmacodynamic data from tumor biopsy samples obtained from patients participating in our ongoing Phase 2 melanoma study are consistent with preclinical data in the B16 melanoma mouse model, where we demonstrated that IL-12 is turning on an interferon-gamma-driven signaling cascade, culminating in the accumulation of tumor infiltrating lymphocytes, or TILs, which have been shown to correlate with response to anti-PD-1 therapies. Based on this biology, we will be testing the hypothesis that intratumoral electroporation with IL-12 will help convert PD-1 non-responders into responders.”businesswire/news/home/20140909005339/en/OncoSec-Medical-Present-Data-ESMO-2014-Congress#.VA7Vy_ldVuY
Posted on: Tue, 09 Sep 2014 10:34:55 +0000
Trending Topics
Recently Viewed Topics
© 2015